Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.vaccine.2009.11.054
Title: Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children
Authors: Lum, L.C.S.
Borja-Tabora, C.F.
Breiman, R.F.
Brooks, W.A.
Vesikari, T.
Sablan, B.P.
Chay, O.M.
Tantracheewathorn, T.
Schmitt, H.-J.
Lau, Y.-L.
Bowonkiratikachorn, P.
Tam, J.S.
Lee, B.W. 
Tan, K.K.
Pejcz, J.
Cha, S.
Gutierrez-Brito, M.
Kaltenis, P.
Vertruyen, A.
Czajka, H.
Bojarskas, J.
Cheng, S.-M.
Rappaport, R.
Baker, S.
Gruber, W.C.
Forrest, B.D.
Keywords: Combined vaccines
Live attenuated influenza vaccine
Measles-mumps-rubella vaccine
Vaccine interference
Issue Date: 2010
Source: Lum, L.C.S., Borja-Tabora, C.F., Breiman, R.F., Brooks, W.A., Vesikari, T., Sablan, B.P., Chay, O.M., Tantracheewathorn, T., Schmitt, H.-J., Lau, Y.-L., Bowonkiratikachorn, P., Tam, J.S., Lee, B.W., Tan, K.K., Pejcz, J., Cha, S., Gutierrez-Brito, M., Kaltenis, P., Vertruyen, A., Czajka, H., Bojarskas, J., Cheng, S.-M., Rappaport, R., Baker, S., Gruber, W.C., Forrest, B.D. (2010). Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children. Vaccine 28 (6) : 1566-1574. ScholarBank@NUS Repository. https://doi.org/10.1016/j.vaccine.2009.11.054
Abstract: Children aged 11 to <24 months received 2 intranasal doses of live attenuated influenza vaccine (LAIV) or placebo, 35 ± 7 days apart. Dose 1 was administered concomitantly with a combined measles, mumps, and rubella vaccine (Priorix). Seroresponses to measles and mumps were similar between groups. Compared with placebo, response rates to rubella in LAIV + Priorix recipients were statistically lower at a 15 IU/mL threshold (83.9% vs 78.0%) and the prespecified noninferiority criteria were not met. In a post hoc analysis using an alternate widely accepted threshold of 10 IU/mL, the noninferiority criteria were met (93.4% vs 89.8%). Concomitant administration with Priorix did not affect the overall influenza protection rate of LAIV (78.4% and 63.8% against antigenically similar influenza strains and any strain, respectively). © 2009 Elsevier Ltd. All rights reserved.
Source Title: Vaccine
URI: http://scholarbank.nus.edu.sg/handle/10635/25664
ISSN: 0264410X
DOI: 10.1016/j.vaccine.2009.11.054
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

36
checked on Dec 5, 2017

WEB OF SCIENCETM
Citations

37
checked on Dec 5, 2017

Page view(s)

166
checked on Dec 18, 2017

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.